Briefing26 August 2026·14 min read
A Misfit CDMO Once Meant a Difficult Technology Transfer. Now It Can Cost the Production Window.
Most peptide CDMO selection frameworks were written when capacity was available. They ask reasonable questions at the wrong level of specificity — and where qualified commercial capacity is scarce, that imprecision costs a place in the queue. Six recurring failure modes, and the evidence that settles each one.